Vigil Neuroscience’s Alzheimer’s Candidate Reveals Encouraging Security Profile, Plans To Begin Mid-Stage Research In Q3 – Vigil Neuroscience (NASDAQ:VIGL)

On Thursday, Vigil Neuroscience Inc. VIGL launched information from its accomplished Section 1 trial evaluating VG-3927 as a possible remedy for Alzheimer’s illness.

Key takeaways from the Section 1 medical trial of VG-3927 embody:

• Demonstrated a good security and tolerability profile throughout all cohorts, together with the aged cohort.
• All associated antagonistic occasions have been delicate or average in severity and self-resolving with out drug discontinuations. No severe AEs have been reported.
• Extremely mind penetrant with a good and predictable PK profile that helps once-daily dosing.
• Achieved strong and dose-dependent discount of sTREM2 of as much as roughly 50% within the cerebral spinal fluid (CSF), demonstrating a powerful PK/PD relationship, sustained goal engagement, and TREM2 agonist exercise.
• PK and sTREM2 discount noticed within the Alzheimer’s cohort was in step with wholesome volunteers and comparable throughout evaluated TREM2 and ApoE genetic variants supporting growth in Alzheimer’s illness throughout genotypes.
• PK and sTREM2 discount noticed within the aged cohort was in step with wholesome volunteers.
• Mixed medical and in vivo preclinical information affirm that VG-3927 elicits neuroprotective activation of microglia downstream of TREM2 signaling. 

The corporate plans to advance a once-daily oral dose of 25mg and expects to provoke the Section 2 trial within the third quarter of 2025.

William Blair writes that the 50% sTREM2 discount improves on the interim Section 1 information from wholesome volunteers that confirmed important reductions in sTREM2, with cohort means starting from 20% to 25% decreases within the highest three dose ranges.

Analyst Sarah Schram sees this as encouraging preliminary assist of goal engagement.

The analyst writes, “We’re extremely inspired by right this moment’s replace, which comes after a strong Section I research incorporating 14 cohorts and indicating constant goal engagement throughout participant teams.”

Vigil’s market cap is decrease than the money it reported on the finish of final yr’s third quarter, William Blair says, and the corporate is considerably undervalued in comparison with its potential and maintains an Outperform ranking.

Worth Motion: VIGL inventory is up 21.40% at $2.47 on the final examine on Thursday.

Learn Subsequent: